Priliximab

Priliximab

Monoclonal antibody
Type	Whole antibody
Source	Chimeric (mouse/human)
Target	CD4
Clinical data
ATC code	none
Identifiers
CAS Number	147191-91-1^N
ChemSpider	none
UNII	TW5DE23BLM
^NY (what is this?)  (verify)

Priliximab (cMT 412) is a human-mouse chimeric anti-CD4 monoclonal antibody. It has been tested on patients with Crohn's disease^[1] and multiple sclerosis^[2][3] but has not yet received U.S. Food and Drug Administration licensing. The patent belongs to the biotechnology company Centocor.

References

1. Stronkhorst A, Radema S, Yong S, Bijl H, ten Berge I, Tytgat G, van Deventer S (1997). "CD4 antibody treatment in patients with active Crohn's disease: a phase 1 dose finding study". Gut. 40 (3): 320–7. doi:10.1136/gut.40.3.320. PMC 1027080. PMID 9135519.
2. Llewellyn-Smith N, Lai M, Miller D, Rudge P, Thompson A, Cuzner M (1997). "Effects of anti-CD4 antibody treatment on lymphocyte subsets and stimulated tumor necrosis factor alpha production: a study of 29 multiple sclerosis patients entered into a clinical trial of cM-T412". Neurology. 48 (4): 810–6. doi:10.1212/wnl.48.4.810. PMID 9109860. S2CID 9938490.
3. van Oosten B, Lai M, Hodgkinson S, Barkhof F, Miller D, Moseley I, Thompson A, Rudge P, McDougall A, McLeod J, Adèr HJ, Polman C (1997). "Treatment of multiple sclerosis with the monoclonal anti-CD4 antibody cM-T412: results of a randomized, double-blind, placebo-controlled, MR-monitored phase II trial". Neurology. 49 (2): 351–7. doi:10.1212/wnl.49.2.351. PMID 9270561. S2CID 8294890.